Business
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets.
About this update from 4dmedical Ltd.
[{"type":"text","content":"In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. ","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"MELBOURNE, Australia, March 31, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets.","length":393,"tagName":"p"},{"type":"image","alt":"4DMedical’s CT:VQ™ technology combines the anatomical clarity of CT with functional ventilation-perfusion mapping from routine non-contrast CT scans, giving clinicians quantitative insights into regional lung function without radiotracers.","displaySize":"","headline":null,"caption":"4DMedical’s CT:VQ™ technology combines the anatomical clarity of CT with functional ventilation-perfusion mapping from routine non-contrast CT scans, giving clinicians quantitative insights into regional lung function without radiotracers.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":311,"url":"https://media.zenfs.com/en/prnewswire.com/f41f0f544ff4adfc446fff2977eed6f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kTktlCQV9rHeY84nYAg6PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU0OA--/https://media.zenfs.com/en/prnewswire.com/f41f0f544ff4adfc446fff2977eed6f6","width":400,"height":311}}},{"type":"text","content":"In a separate but concurrent announcement, 4DMedical has secured firm commitments from select institutional investors for an AU$83 million single-tranche private placement. This additional capital will support the Company's growth strategy, particularly the expansion of CT:VQ™ in Europe.","length":297,"tagName":"p"},{"type":"text","content":"CT:VQ™ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure.","length":261,"tagName":"p"},{"type":"text","content":"Pulmonary disease is fundamentally functional—defined ...